Barentz set to expand pharma footprint in China with Fengli Group acquisition
This move allows Barentz to accelerate its mission to deliver innovative, high-quality solutions and foster growth in the global pharmaceutical landscape.
CHINA – Barentz, a leading global speciality ingredients solution provider, has announced that it is in exclusive talk to acquire full ownership of Fengli Group, a Chinese distributor of specialty chemicals, including pharmaceutical excipients and active ingredients.
This strategic move will leverage Fengli Group’s robust network and deep-rooted expertise in distributing pharmaceutical excipients and active ingredients across mainland China, serving over 2,000 customers, to secure Barentz’s access to one of the most dynamic and rapidly growing pharma markets in Asia Pacific.
The acquisition, expected to reach completion in the latter half of 2025 pending customary regulatory clearances, marks a transformative step for Barentz in its mission to deliver innovative, high-quality solutions and foster accelerated growth in the global pharmaceutical landscape.
Mr. Dexin Ma, President at Fengli, stated, “We are thrilled to be partnering with Barentz soon.”
“A collaboration allows us to offer an enhanced array of solutions for excipients, active ingredients and intermediates, combining our collective resources and expertise, while upholding our shared values.”
“This partnership will accelerate cooperation with our current principals and is expected to enable expansion in mainland China and overseas markets with Barentz’s strong network of principals.”
Fengli Group is a key player in the Chinese pharmaceutical sector with a skilled team spanning five major locations across mainland China.
The company specializes in sourcing high-quality pharmaceutical excipients and active ingredients from 35 international principals, and is involved in production, research, and development.
Its state-of-the-art facilities, comprising an analytical lab for product formulation and dedicated research, development, and application labs, underscore its commitment to innovation and excellence in the pharma and health products market.
Meanwhile, Barentz recently appointed Martin Thomsen as the new chair of its Supervisory Board.
Thomsen succeeds Jürgen Steinemann, who will continue as a member of the Supervisory Board, ensuring continuity and support for the company’s ambitious goals
Thomsen brings extensive international leadership experience and expertise in transforming and scaling businesses.
Thomsen is expected to lead Barentz’s Supervisory Board by providing strategic guidance and leveraging his extensive experience in transforming and scaling businesses.
His role involves supporting the management team in driving long-term value, strengthening the company’s position as a global leader in speciality chemical distribution, and ensuring the company’s growth aligns with its ambitious goals.
Sign up to receive our email newsletters with the latest news updates and insights from Africa and the World HERE.
